Demographics | n=104 |
Age (years, mean±SD) | 60.66 (±13.50) |
Sex (F) n (%) | 49 (47.12 %) |
BMI* kg/m2 (mean±SD) | 32.14 (±7.80) |
Comorbidities n (%) | |
Hypertension | 46 (45.10%) |
Diabetes | 35 (34.65%) |
Lung Dx | 31 (30.69%) |
Heart Dx | 23 (22.55%) |
CKD | 15 (16.3%), 9 (9.78%) on HD |
Race | |
African-American | 53 (50.96%) |
Hispanic | 23 (22.12%) |
Caucasian | 9 (8.65%) |
Other | 4 (3.85%) |
Unknown | 15 (14.42%) |
Smoking n (%) | |
No | 51 (51.52%) |
Yes | 43 (43.43%) |
Initial vitals | |
Heart rate (mean±SD) bpm | 98.0 (±20.17) |
Respiratory rate (mean±SD) bts/min | 22.03 (±5.47) |
Temperature (mean±SD) °F | 99.4 (±2.18) |
Pulse oximetry (mean±SD) % | 89.9 (±10.09) |
Laboratory abnormalities mean (±SD) | |
Ferritin (ng/mL) | 1216.0 (±2790.6) |
CRP* (mg/dL) | 11.77 (±8.38) |
LDH* (U/L) | 452.06 (±292.36) |
D-dimer (ng/mL) | 5659.6 (±17267.49) |
Fibrinogen (mg/dL) | 490.23 (±178.44) |
Lymphocyte count (K/mm3) | 1.02 (±0.54) |
IL-6 (pg/mL) | 82.5 (±149.54) |
AST (U/L) | 56.8 (±74.90) |
ALT (U/L) | 38.6 (±31.93) |
Platelets (K/mm3) | 221.7 (±106.19) |
Triglycerides (mg/dL) | 186.7 (±253.78) |
BUN (mg/dL) | 28.4 (±24.07) |
Creatinine (mg/dL) | 2.61 (±3.95) |
Treatments | |
Remdesivir | 9 (9.68%) |
Sarilumab | 40 (39.22%) |
Anakinra | 12 (11.76%) |
Tocilizumab | 6 (5.88%) |
Etoposide | 1 (0.97%) |
IVIG | 19 (18.63%) |
Pulse steroids | 66 (64.71%) |
Hydroxychloroquine | 22 (21.57%) |
Azithromycin | 59 (57.2%) |
Antibiotics | 76 (73.08%) |
ALT, alanine transaminase; AST, aspartate transaminase; bpm, beats per min; bts/min, breaths per min; BUN, blood urea nitrogen; CKD, chronic kidney disease; CRP, C reactive protein; Dx, diagnosis; F, Fahrenheit; HD, haemodialysis; IL-6, interleukin 6; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase.